Experimental Studies of the Effects of the Dopamine D2 Receptor Agonist Cabergoline on Catecholamine Content and BDNF mRNA Expression in the Midbrain and Hypothalamus

Autor: A. G. Veretinskaya, V. V. Pavshintsev, P. K. Anokhin, I. Yu. Shamakina
Rok vydání: 2020
Předmět:
Zdroj: Neuroscience and Behavioral Physiology. 50:830-834
ISSN: 1573-899X
0097-0549
DOI: 10.1007/s11055-020-00974-3
Popis: Objectives. To study the effects of cabergoline on the catecholamine content and brain-derived neurotrophic factor (BDNF) mRNA expression in the midbrain and hypothalamus. Materials and methods. Experiments were performed on 20 adult male Wistar rats. Animals of the experimental group (n = 10) received i.p. cabergoline (0.5 mg/kg). Control animals (n = 10) received the same volume of solvent. Dopamine and noradrenaline contents were measured by high-performance liquid chromatography with electrochemical detection and the relative BDNF mRNA level was analyzed using the real-time polymerase chain reaction after reverse transcription. Results and conclusions. Administration of cabergoline was followed 24 h later by a significant increase in the noradrenaline content in the midbrain of animals of the experimental group as compared with the control group (639.2 ± 64.5 ng/g vs. 398.0 ± 66.0 ng/g, p < 0.05), while there was no change in the dopamine level (211.4 ± 16.3 ng/g vs. 169.7 ± 54.6 ng/g). No Changes in transmitter contents in the hypothalamus were seen. Administration of cabergoline led to a two-fold increase in the BDNF mRNA level in the midbrain but not in the hypothalamus at 24 h after injection.
Databáze: OpenAIRE
Externí odkaz: